Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for anti-Hu associated paraneoplastic neurological syndromes
2008-000793-20Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in paraneoplastic neurological syndrome (PNS) and encephalomyelitis, sponsored by Erasmus MC. Primary endpoints: Functional improvement after 8 weeks and Neurological impairment improvement after 8 weeks. Started Mar 2008; status: active.
02
Drugs
sirolimus
03
Conditions
paraneoplastic neurological syndrome (PNS)encephalomyelitis
Beyond the preview
Go deeper on 2008-000793-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000793-20.